To explore the possibility of protein degradation regulating PIAS3 expression in MM, we investigated the effect of proteasome inhibitor (MG‐132 and bortezomib) treatment on three MM cell lines with low endogenous PIAS3 expression. The gene discussed is PIAS3; the disease is Miyoshi myopathy.